These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 4003004)

  • 21. Abolition of the permeability-enhancing properties of Hageman factor by specific antiserum.
    Kellermeyer RW; Ratnoff OD
    J Lab Clin Med; 1967 Sep; 70(3):365-71. PubMed ID: 4166883
    [No Abstract]   [Full Text] [Related]  

  • 22. Studies on the participation of Hageman factor in fibrinolysis.
    McDonagh RP; Ferguson JH
    Thromb Diath Haemorrh; 1970 Oct; 24(1):1-9. PubMed ID: 4249468
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hageman trait].
    Takamiya O; Takahashi Y
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):28-30. PubMed ID: 9851077
    [No Abstract]   [Full Text] [Related]  

  • 24. [Role of the Hageman factor in regulation of blood coagulability].
    Zubairov DM; Popova LG; Iagudin KF
    Fiziol Zh SSSR Im I M Sechenova; 1972 Jan; 58(1):51-5. PubMed ID: 5061360
    [No Abstract]   [Full Text] [Related]  

  • 25. Structural and functional characterization of factor XII.
    Tans G; Rosing J
    Semin Thromb Hemost; 1987 Jan; 13(1):1-14. PubMed ID: 3551074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between kallikrein release and factor XII in normal persons and carriers of the Hageman trait.
    Torres M; Ercoreca L; Lucia JF; Giralt M; Raichs A
    Thromb Haemost; 1979 Dec; 42(4):1286-8. PubMed ID: 261563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiation of the function of Hageman factor fragments by high molecular weight kininogen.
    Liu CY; Scott CF; Bagdasarian A; Pierce JV; Kaplan AP; Colman RW
    J Clin Invest; 1977 Jul; 60(1):7-17. PubMed ID: 874091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of chemical modification of basic amino acid residues on the activation and amidolytic activity of Hageman factor (factor XII).
    Ryder J; Everson B; Jentoft J; Ratnoff OD
    J Lab Clin Med; 1993 Dec; 122(6):697-702. PubMed ID: 8245689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents.
    McMillin CR; Saito H; Ratnoff OD; Walton AG
    J Clin Invest; 1974 Dec; 54(6):1312-22. PubMed ID: 4373492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol).
    Laurel MT; Ratnoff OD; Everson B
    J Lab Clin Med; 1992 May; 119(5):580-5. PubMed ID: 1374787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of the intrinsic coagulation and fibrinolytic pathways of man: the role of surfaces, hageman factor, prekallikrein, high molecular weight kininogen, and factor XI.
    Kaplan AP
    Prog Hemost Thromb; 1978; 4():127-75. PubMed ID: 362477
    [No Abstract]   [Full Text] [Related]  

  • 32. Classic gout in Hageman factor (Factor XII) deficiency.
    Green D; Arsever CL; Grumet KA; Ratnoff OD
    Arch Intern Med; 1982 Aug; 142(8):1556-7. PubMed ID: 7103639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory action of amyloid precursor protein against human Hageman factor (factor XII).
    Niwano H; Embury PB; Greenberg BD; Ratnoff OD
    J Lab Clin Med; 1995 Feb; 125(2):251-6. PubMed ID: 7844473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of plasma Hageman factor and kallikrein in ongoing allergic reactions in the skin.
    Atkins PC; Miragliotta G; Talbot SF; Zweiman B; Kaplan AP
    J Immunol; 1987 Oct; 139(8):2744-8. PubMed ID: 3655370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+).
    Saito H; Scott JG; Movat HZ; Scialla SJ
    J Lab Clin Med; 1979 Aug; 94(2):256-65. PubMed ID: 110893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of the plasma kallikrein-kinin system through activation of factor XII.
    Katori M; Uchida Y
    Nihon Ketsueki Gakkai Zasshi; 1985 Feb; 48(1):187-91. PubMed ID: 3847250
    [No Abstract]   [Full Text] [Related]  

  • 37. [Isolation and some properties of Hageman factor and its active fragment from human blood].
    Krizhevskaia IuV; Iarovaia GA; Dotsenko VL; Khvatov VB
    Biokhimiia; 1981 Aug; 46(8):1510-8. PubMed ID: 7272366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases.
    España F; Ratnoff OD
    J Lab Clin Med; 1983 Jul; 102(1):31-45. PubMed ID: 6343536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
    Revak SD; Cochrane CG; Griffin JH
    J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on the adsorption and activation of the Hageman factor (factor XII) by collagen and elastin.
    Niewiarowski S; Bańkowski E; Rogowicka I
    Thromb Diath Haemorrh; 1965 Nov; 14(3-4):387-400. PubMed ID: 5865602
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.